4 hours ago 1

H.C. Wainwright Reiterates Buy Rating on ImmunityBio, Keeps PT at $8

Mon, Sep 15, 2025, 8:17 AM 2 min read

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the 12 Best NASDAQ Penny Stocks to Buy According to Hedge Funds. On September 10, H.C. Wainwright reiterated the Buy rating on ImmunityBio, Inc. (NASDAQ:IBRX), keeping the price target at $8.

Andres Y. Maldonado from H.C. Wainwright reaffirmed the rating on IBRX after the company announced promising developments with ANKTIVA in treating advanced non-small cell lung cancer (NSCLC). On September 8, ImmunityBio reported that the new paradigm-changing findings from the Phase 2 study showed that ANKTIVA reverses low natural killer and T cells in patients with checkpoint inhibitor-resistant advanced NSCLC.

H.C. Wainwright Reiterates Buy Rating on ImmunityBio, Keeps PT at $8

The study found that 60% of the patients experienced reversal from lymphopenia, with 80% maintaining an absolute lymphocyte count (ALC) above 1,200 cells/uL. The results demonstrate significant improvements in survival rates among lymphopenia survivors. ANKTIVA’s immune reconstitution approach may have broader applications across different tumor types. ANKTIVA’s established presence in bladder cancer and ongoing developments in other malignancies make it a versatile and promising cytokine therapy. Maldonado’s positive take on ImmunityBio indicates the company’s optimistic outlook for its role in oncology.

ImmunityBio, Inc. (NASDAQ:IBRX) is a commercial-stage biotechnology firm that develops next-generation therapies that bolster the natural immune system to overcome cancers and infectious diseases.

While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.